Metastatic follicular thyroid cancer with a longstanding responsiveness to gemcitabine plus oxaliplatin.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
환자: thyroid cancer unresponsive to MKI
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
However, with a durable response to GEMOX, the overall survival of our patient appears to have been extended significantly due to this chemotherapy. [CONCLUSION] GEMOX may have a role in patients with thyroid cancer unresponsive to MKI.
[BACKGROUND] Treatment of advanced follicular thyroid carcinoma (FTC) is based primarily on indirect evidence obtained with multikinase inhibitors (MKI) in clinical trials in which papillary carcinoma
APA
Dias D, Damásio I, et al. (2023). Metastatic follicular thyroid cancer with a longstanding responsiveness to gemcitabine plus oxaliplatin.. European thyroid journal, 12(3). https://doi.org/10.1530/ETJ-22-0227
MLA
Dias D, et al.. "Metastatic follicular thyroid cancer with a longstanding responsiveness to gemcitabine plus oxaliplatin.." European thyroid journal, vol. 12, no. 3, 2023.
PMID
36976625 ↗
Abstract 한글 요약
[BACKGROUND] Treatment of advanced follicular thyroid carcinoma (FTC) is based primarily on indirect evidence obtained with multikinase inhibitors (MKI) in clinical trials in which papillary carcinomas represent the vast majority of cases. However, it should be noted that MKI have a non-negligible toxicity that may decrease the patient's quality of life. Conventional chemotherapy with GEMOX (gemcitabine plus oxaliplatin) is an off-label therapy, which seems to have some effectiveness in advanced differentiated thyroid carcinomas, with a good safety profile, although further studies are needed.
[CASE REPORT] We report a case of a metastatic FTC, resistant to several lines of therapy. However, with a durable response to GEMOX, the overall survival of our patient appears to have been extended significantly due to this chemotherapy.
[CONCLUSION] GEMOX may have a role in patients with thyroid cancer unresponsive to MKI.
[CASE REPORT] We report a case of a metastatic FTC, resistant to several lines of therapy. However, with a durable response to GEMOX, the overall survival of our patient appears to have been extended significantly due to this chemotherapy.
[CONCLUSION] GEMOX may have a role in patients with thyroid cancer unresponsive to MKI.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (1)
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.